Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies - PubMed (original) (raw)
Review
. 2011 Dec 20;156(4):325-37.
doi: 10.1016/j.jbiotec.2011.08.004. Epub 2011 Sep 2.
Affiliations
- PMID: 21925549
- DOI: 10.1016/j.jbiotec.2011.08.004
Review
Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies
Tiziana Alberio et al. J Biotechnol. 2011.
Abstract
Parkinson's disease is the most common neurodegenerative movement disorder, affecting about 6 million people worldwide with a slow progression of the symptoms. Its prevalence is expected to double in the most populated areas within the next two decades, according to increasing aged population. Consequently, Parkinson's disease is a socio-economic trouble and a major challenge for the public health system. Parkinson's disease treatment is merely symptomatic, as clinical symptoms appear when about 70% of the involved neurons are lost and potential disease-modifying/neuroprotective therapies would have no effect. In turn, the availability of an objective measure that allows early diagnosis would strongly impact on the costs that biotech- and pharma-companies will sustain in order to develop disease-modifying therapies. The establishment of suitable models to investigate the mechanisms of Parkinson's disease progression and, on the other hand, the discovery and validation of selective and specific molecular biomarkers for early and differential diagnosis are indeed two important goals for a better management of the disease. In this review, we focus on cellular and animal models of Parkinson's disease by describing their advantages and limitations as useful tools to identify pathogenetic pathways that deserve further exploitation. In parallel, we discuss how proteomics may provide a potent tool to observe altered pathways in models or altered biomarkers in patients with an unbiased, hypothesis-free approach.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
- Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.
Ren R, Sun Y, Zhao X, Pu X. Ren R, et al. Clin Chem Lab Med. 2015 Sep 1;53(10):1495-506. doi: 10.1515/cclm-2014-0783. Clin Chem Lab Med. 2015. PMID: 25581757 Review. - Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M, Lopiano L. Fasano M, et al. Expert Rev Proteomics. 2008 Apr;5(2):239-48. doi: 10.1586/14789450.5.2.239. Expert Rev Proteomics. 2008. PMID: 18466054 Review. - Alzheimer's and Parkinson's diseases: an environmental proteomic point of view.
Demartini DR, Schilling LP, da Costa JC, Carlini CR. Demartini DR, et al. J Proteomics. 2014 Jun 2;104:24-36. doi: 10.1016/j.jprot.2014.04.014. Epub 2014 Apr 18. J Proteomics. 2014. PMID: 24751585 Review. - Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease.
Singh MP, Patel S, Dikshit M, Gupta YK. Singh MP, et al. Indian J Biochem Biophys. 2006 Apr;43(2):69-81. Indian J Biochem Biophys. 2006. PMID: 16955754 Review. - Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis.
Pienaar IS, Dexter DT, Burkhard PR. Pienaar IS, et al. Expert Rev Proteomics. 2010 Apr;7(2):205-26. doi: 10.1586/epr.10.8. Expert Rev Proteomics. 2010. PMID: 20377388 Review.
Cited by
- The Concept of an Epilepsy Brain Bank.
Hernandez-Ronquillo L, Miranzadeh Mahabadi H, Moien-Afshari F, Wu A, Auer R, Zherebitskiy V, Borowsky R, Mickleborough M, Huntsman R, Vrbancic M, Cayabyab FS, Taghibiglou C, Carter A, Tellez-Zenteno JF. Hernandez-Ronquillo L, et al. Front Neurol. 2020 Aug 20;11:833. doi: 10.3389/fneur.2020.00833. eCollection 2020. Front Neurol. 2020. PMID: 32973652 Free PMC article. Review. - Exploring the Mitochondrial Degradome by the TAILS Proteomics Approach in a Cellular Model of Parkinson's Disease.
Lualdi M, Ronci M, Zilocchi M, Corno F, Turilli ES, Sponchiado M, Aceto A, Alberio T, Fasano M. Lualdi M, et al. Front Aging Neurosci. 2019 Jul 31;11:195. doi: 10.3389/fnagi.2019.00195. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31417398 Free PMC article. - Differential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's disease.
Xing L, Wang D, Wang L, Lan W, Pan S. Xing L, et al. Int J Clin Exp Pathol. 2015 Nov 1;8(11):15462-6. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26823915 Free PMC article. - Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease.
Alberio T, Pippione AC, Zibetti M, Olgiati S, Cecconi D, Comi C, Lopiano L, Fasano M. Alberio T, et al. Sci Rep. 2012;2:953. doi: 10.1038/srep00953. Epub 2012 Dec 11. Sci Rep. 2012. PMID: 23233872 Free PMC article. - Application of proteomics to cerebrovascular disease.
Ning M, Lopez M, Cao J, Buonanno FS, Lo EH. Ning M, et al. Electrophoresis. 2012 Dec;33(24):3582-97. doi: 10.1002/elps.201200481. Electrophoresis. 2012. PMID: 23161401 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical